Dr. Reddy's Laboratories Limited (NSE:DRREDDY)
India · Delayed Price · Currency is INR 1,323.00
+11.60 (0.88%)
Sep 18, 2025, 3:30 PM IST
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 85.45B INR in the quarter ending June 30, 2025, with 11.37% growth. This brings the company's revenue in the last twelve months to 334.26B, up 15.86% year-over-year. In the fiscal year ending March 31, 2025, Dr. Reddy's Laboratories had annual revenue of 325.54B with 16.61% growth.
Revenue (ttm)
334.26B
Revenue Growth
+15.86%
P/S Ratio
3.26
Revenue / Employee
12.02M
Employees
27,811
Market Cap
1,091.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Divi's Laboratories | 96.52B |
| Cipla | 274.80B |
| Apollo Hospitals Enterprise | 225.51B |
| Mankind Pharma | 129.10B |
| Zydus Lifesciences | 236.08B |
| Fortis Healthcare | 80.94B |
| Alkem Laboratories | 133.04B |
Dr. Reddy's Laboratories News
- 1 day ago - Dr Reddy shares in focus: India bulk drug makers reportedly start preparing for Ozempic patent expiry - Business Upturn
- 1 day ago - Dr. Reddy’s launches novel molecule ‘Tegoprazan’ in India for acid-related gastrointestinal diseases - Business Upturn
- 2 days ago - Nifty 50 top losers today, September 15: Cipla, Asian Paints, Mahindra & Mahindra, Shriram Finance, Dr. Reddy’s and more - Business Upturn
- 3 days ago - Dr. Reddy’s shares fall nearly 2% after USFDA issues Form 483 with 5 observations for Hyderabad unit - Business Upturn
- 3 days ago - Stocks in news today, Sept 15: HUL, HAL, Dr Reddy’s, Apollo Hospitals, Adani Power, APL, Engineers India, Railtel among key shares - Business Upturn
- 5 days ago - Dr. Reddy’s Laboratories receives Form 483 with five observations from USFDA after Bachupally facility inspection - Business Upturn
- 7 days ago - Dr. Reddy’s Laboratories acquires STUGERON portfolio from Janssen Pharmaceutica for $50.5 million - Business Upturn
- 9 days ago - Nifty 50 top gainers today, September 9: Infosys, Dr. Reddy’s Laboratories, Wipro, Adani Ports and more - Business Upturn